NCT00456547

Brief Summary

The purpose of this study is to examine components of the coagulation system in women undergoing postpartum hysterectomy and to compare laboratory parameters of coagulation in these women to women at increased risk for a postpartum hysterectomy, but who do not have postpartum hemorrhage and a postpartum hysterectomy. During normal pregnancy, the hemostatic balance tips toward hypercoagulation. Non-obstetric surgical blood loss is associated with increased coagulation activity. We have observed that women undergoing a postpartum hysterectomy become hypocoagulable secondary to a consumptive coagulopathy and/or excessive fibrinolysis. This coagulopathy may lead to the administration of multiple blood products. Worldwide, postpartum hemorrhage is a leading cause of maternal death. Plasma levels of tissue plasminogen activator, urokinase plasminogen activator and their inhibitors increase during pregnancy. During labor and delivery activation of coagulation occurs with consumption of platelets, coagulation factors and inhibitors. Obstetric complications during delivery can excessively activate the coagulation system and disseminated intravascular coagulation may ensue. Current treatment for postpartum coagulopathy is non-specific and primarily consists of replacing blood components. If specific causes or markers of abnormal coagulation can be identified in women at risk, then it might be possible to target (with specific medications) specific abnormalities early in the process and decrease hemorrhage and the need for blood transfusions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Dec 2003

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2003

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2006

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 3, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 5, 2007

Completed
4.9 years until next milestone

Results Posted

Study results publicly available

February 20, 2012

Completed
Last Updated

April 14, 2014

Status Verified

March 1, 2014

Enrollment Period

3 years

First QC Date

April 3, 2007

Results QC Date

November 6, 2011

Last Update Submit

March 17, 2014

Conditions

Keywords

Cesarean hysterectomyPostpartum hemorrhageCoagulation

Outcome Measures

Primary Outcomes (1)

  • Fibrinogen Level at 2 Hours After Delivery

    Fibrinogen level decrease is a marker of consumptive coagulation which is is a pathological activation of coagulation (blood clotting) mechanisms that happens in response to a variety of diseases or stimulus. We hypothesized that women with excessive bleeding following delivery who require a hysterectomy are more likely to exhibit lower levels of fibrinogen and a consumptive coagulopathy than women following cesarean delivery who do not bleed.

    2 hours after delivery

Secondary Outcomes (3)

  • Platelet Counts at 2 Hours After Delivery

    2 hours after delivery

  • Plasminogen Levels 2 Hours After Delivery

    2 hours after delivery

  • Antithrombin III Levels at 2 Hours Post Delivery

    2 hours after delivery

Study Arms (2)

Postpartum hysterectomy

Women that require postpartum hysterectomy for post-delivery bleeding.

Procedure: Blood Draw

Cesarean delivery case controls

Women that deliver by cesarean that presented with risk factors for bleeding but did not require post delivery hysterectomy

Procedure: Blood Draw

Interventions

Blood DrawPROCEDURE

Blood was obtained for coagulation studies at 2 hours following hysterectomy or cesarean delivery.

Also known as: postpartum coagulation disorder
Cesarean delivery case controlsPostpartum hysterectomy

Eligibility Criteria

Age18 Years - 60 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Pregnant Women

You may qualify if:

  • All women scheduled for a Cesarean-hysterectomy will be asked to enroll in the study, as well as the women with the following diagnoses, that puts them at increased risk for Cesarean hysterectomy: placenta previa, placenta accreta, vaginal trial of labor after previous Cesarean delivery.

You may not qualify if:

  • Anyone who does not fit the above criteria.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Northwestern University

Chicago, Illinois, 60611, United States

Location

Related Publications (4)

  • Tuman KJ, Spiess BD, McCarthy RJ, Ivankovich AD. Effects of progressive blood loss on coagulation as measured by thrombelastography. Anesth Analg. 1987 Sep;66(9):856-63.

    PMID: 3619091BACKGROUND
  • Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003 Apr;29(2):125-30. doi: 10.1055/s-2003-38897.

    PMID: 12709915BACKGROUND
  • Lanir N, Aharon A, Brenner B. Procoagulant and anticoagulant mechanisms in human placenta. Semin Thromb Hemost. 2003 Apr;29(2):175-84. doi: 10.1055/s-2003-38833.

    PMID: 12709921BACKGROUND
  • Saftlas AF, Olson DR, Atrash HK, Rochat R, Rowley D. National trends in the incidence of abruptio placentae, 1979-1987. Obstet Gynecol. 1991 Dec;78(6):1081-6.

    PMID: 1945212BACKGROUND

MeSH Terms

Conditions

Obstetric Labor ComplicationsHemorrhagePostpartum HemorrhageThrombosis

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Pregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsPuerperal DisordersUterine HemorrhageEmbolism and ThrombosisVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Results Point of Contact

Title
Dr. Robert J McCarthy, Pharm D
Organization
Northwestern University Feinberg School of Medicine

Study Officials

  • Cynthia A Wong, M.D.

    Northwestern University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Anesthesiology

Study Record Dates

First Submitted

April 3, 2007

First Posted

April 5, 2007

Study Start

December 1, 2003

Primary Completion

December 1, 2006

Study Completion

December 1, 2006

Last Updated

April 14, 2014

Results First Posted

February 20, 2012

Record last verified: 2014-03

Locations